Fenticonazole Nitrate Shows Broad-Spectrum Activity in Vulvovaginitis

Background

Vulvovaginitis is a common clinical syndrome caused by fungal, bacterial, and protozoal pathogens, with Candida albicans, Gardnerella vaginalis, and Trichomonas vaginalis among the principal organisms discussed in the study. Mixed infections can be difficult to treat because more than one pathogen may require eradication. The investigators evaluated whether topical fenticonazole nitrate, an imidazole derivative with reported antifungal and activity against selected non-fungal organisms, could provide a convenient broad-spectrum option. [1]

Study Snapshot

Key Findings

• The two-dose regimen eradicated all identified offending pathogens in 67% of the per-protocol population (68/101) by day 8.
• Eradication was highest for C. albicans at 90% (26/29), followed by T. vaginalis at 70% (7/10) and G. vaginalis at 67% (22/33).
• Eradication in mixed infections was lower at 45% (13/29), highlighting the greater challenge of polymicrobial disease.
• Among patients eradicated at day 8, relapse by day 28 was 0% for candidiasis and trichomoniasis, 27% for G. vaginalis (6/22), and 23% for mixed infections (3/13). The paper’s narrative reports an overall relapse rate of approximately 16%; the displayed outcome table reports 13% (9/68), reflecting a denominator/reporting discrepancy in the source.
• Mean symptom score fell from 7.05 at baseline to 1.71 on day 8 and 1.00 on day 28; mean sign score fell from 4.18 to 1.21 and 0.71, respectively (p < 0.001 for follow-up versus baseline).

Eradication and Relapse Data

Eradication was assessed by direct phase-contrast microscopy and/or microbiological culture. CI, confidence interval; ITT, intention-to-treat; PP, per-protocol.

Safety and Tolerability

Treatment was well tolerated in the 116-patient ITT population. One patient (0.9%) experienced intense vaginal burning that was present at baseline and judged by the investigator to be unrelated to fenticonazole. The patient had persistent G. vaginalis culture at day 8 and was treated further at the physician’s discretion. No clinically important laboratory abnormalities were reported in the study summary.

Why This Matters for Practice

The findings support further evaluation of a simple two-dose intravaginal regimen for vulvovaginitis involving common fungal, bacterial, or protozoal pathogens. The strongest response was observed in single-pathogen candidiasis, while mixed infections had substantially lower eradication. Because this was a small, open-label pilot study without a comparator arm, the results are hypothesis-generating rather than definitive evidence of comparative effectiveness. The source authors specifically called for larger, controlled studies and clarification of whether an additional dose could improve outcomes in T. vaginalis, G. vaginalis, or mixed infections.

Takeaway

In this 2004 pilot study, two 1-g fenticonazole nitrate vaginal ovules administered on alternate days produced high eradication for C. albicans, moderate eradication for T. vaginalis and G. vaginalis, lower eradication for mixed infections, marked symptom improvement, and favorable short-term tolerability. The regimen merits confirmation in adequately powered comparative trials; this summary should not be used as a substitute for current diagnostic or treatment guidance.

Reference

[1] Fernández-Alba J, Valle-Gay A, Dibildox M, Vargas JA, González J, García M, López LH, et al. Fenticonazole Nitrate for Treatment of Vulvovaginitis: Efficacy, Safety, and Tolerability of 1-Gram Ovules, Administered as Ultra-Short 2-Day Regimen. Journal of Chemotherapy. 2004;16(2):179–186. Source: attached journal reprint.

Fenticonazole Nitrate for Treatment of Vulvovaginitis — Clinical Evidence Summary